Levetiracetam Saft Ct (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates the release of neurotransmitters at the presynaptic level. This action stabilises neuronal firing and reduces the hyper‑excitability that leads to seizure activity.

The appropriate dose of Levetiracetam Saft Ct is determined by the prescribing clinician based on the patient’s age, weight, renal function and seizure type. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for levetiracetam in pregnancy are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk. Breastfeeding decisions should be made in consultation with a healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levetiracetam has a distinct mechanism (SV2A binding) and a relatively favorable interaction profile compared with many enzyme‑inducing antiepileptics such as carbamazepine or phenytoin. It is often chosen for its broad spectrum of activity and minimal effect on hepatic enzymes.

Store at room temperature: keep the oral solution in its original container, protect it from moisture and direct light, and ensure the cap is tightly closed to maintain stability.

Levetiracetam Saft Ct is taken orally. The prescribed volume is measured with a calibrated syringe or dosing cup and administered with or without food, according to the prescriber’s directions.

Serious risks include severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, significant mood changes like depression or suicidal thoughts, and rare blood disorders. Patients should be monitored closely for any of these events.

Patients with known hypersensitivity to levetiracetam or any component of the formulation should avoid its use. Caution is also advised for individuals with severe renal impairment, as dose adjustments may be required.